Potential therapeutic effects of prescribed and over-the-counter androgens in women

Clinical Obstetrics and Gynecology

Volumn 44, Issue 4, 2001, Pages 880-892

  Khorram, Omid ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANDROSTENEDIONE; CALUSTERONE; DANAZOL; DROSTANOLONE PROPIONATE; ESTR 4 ENE 3,17 DIONE; ESTRATEST; ESTROGEN; ETHYLESTRENOL; METANDIENONE; METENOLONE; METENOLONE ACETATE; NANDROLONE; NANDROLONE DECANOATE; NANDROLONE PHENPROPIONATE; OXANDROLONE; OXYMETHOLONE; PRASTERONE; STANOZOLOL; TESTOLACTONE; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; TIBOLONE;

ACNE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FORMULATION; ESTRATEST HS; HIRSUTISM; HORMONE SUBSTITUTION; HUMAN; HYPERINSULINEMIA; MENOPAUSAL SYNDROME; REVIEW; TRIBULUS TERRESTRIS; VAGINA BLEEDING; VIRILIZATION;

ACNE VULGARIS; ANDROGENS; FEMALE; HIRSUTISM; HUMANS; LIVER; MENOPAUSE;

EID: 0035194229     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-200112000-00025     Document Type: Review

References (64)

1. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood
2. Androgen metabolism and the menopause
3. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause
4. The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin, and sex hormone-binding globulin in postmenopausal women
5. Ovarian and adrenal contribution to peripheral androgens during the menstrual cycle
6. Risks of menopausal androgen supplementation
7. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women
8. The management of persistent menopausal symptoms with oestradiol and testosterone implants: 6. Clinical, lipid and hormonal results
9. Androgen and estrogen-androgen hormone replacement therapy: A review of the safety literature, 1941-1996
10. A comparison of estrified estrogens with and without methyltestosterone. Effects on endometrial histology and serum lipoprotein in postmenopausal women
11. Hormonal chemoprevention of cancer in women
12. Androgen replacement in women: A commentary
13. Sexual interest in postmenopausal women is related to 5 alpha-reductase activity
14. A new ratio of etiocholanolone/androsterone as an indication of sexual interest in postmenopausal women
15. Estrogen and estrogen-androgen replacement in postmenopausal women dissatisfied with estrogen only therapy. Sexual behavior and neuroendocrine responses
16. Vasodilator effects of estrogen are not diminished by androgen in postmenopausal women
17. Comparison of oral estrogen and estrogen plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause
18. Sublingual administration of micronized estradiol and progesterone, with and without micronized testosterone: Effect on biochemical markers of bone metabolism and bone mineral density
19. Effect of percutaneous androgen replacement therapy on body composition and body weight in postmenopausal women
20. Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women
21. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality
22. Which androgen replacement therapy for women?
23. Tibolone: A review
24. Placebo controlled cross-over study of effects of Org OD 14 in menopausal women
25. A study of the effect of tibolone on the vagina of postmenopausal women
26. Double-blind crossover study with Org OD 14 and placebo in postmenopausal patients
27. Effect on sexual life: A comparison between tibo-lone and a continuous estradiol-norethisterone acetate regimen
28. Comparative effects of estrogen plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women
29. Prevention of postmenopausal bone loss using tibolone on conventional peroral or transdermal hormone replacement therapy with 17β-estradiol and dyhydrogesterone
30. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen and progestogen
31. Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women
32. Effect of replacement dose of dehydroepiandrosterone in men and women of advancing age
33. The effects of dehydroepiandrosterone on endocrine-metabolic parameters in postmenopausal women
34. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease
35. Dehydroepiandrosterone sulfate does not predict cardiovascular death in postmenopausal women. The Rancho Bernardo Study
36. The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life
37. The effect of dehydroepiandrosterone on adipose tissue cellularity in mice
38. vy/o mice by dehydroepiandrosterone
39. Replacement of DHEA in aging men and women. Potential remedial effects
40. The effect of six months of treatment with a 100-mg daily dose of DHEA on circulating sex steroids, body composition and muscle strength in age-advanced men and women
41. Effect of DHEA replacement on bone mineral density and body composition in elderly women and men
42. Replacement of dehydroepiandrosterone enhances T-lymphocyte insulin binding in postmenopausal women
43. Disparate effects of insulin reduction with diltiazem on serum dehydroepiandrosterone sulfate levels in obese hypertensive men and women
44. Physiological importance of dehydroepiandrosterone
45. Aromatase in bone cell: Association with osteoporosis in postmenopausal women
46. Dehdroepiandrosterone (DHEA), DHEA-sulfate, and aging: Contribution of the DHEAge study to a sociobiomedical issue
47. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women
48. Inhibition of tumor development by dehydroepiandrosterone and related steroids
49. Dehydroepiandrosterone sulfate and breast cancer risk
50. Dehydroepiandrosterone (DHEA) and its role in the aging immune system
51. An open study of dehydroepiandrosterone in systemic lupus erythematosus
52. Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women
53. Activation of immune function by dehydroepiandrosterone (DHEA) in age-advanced men
54. An open-label dose-escalation trial of oral DHEA tolerance and pharmacokinetics in patients with HIV disease
55. DHEA treatment is not beneficial to the immune response to influenza in elderly subjects
56. A prospective study of dehydroepiandrosterone sulfate and cognitive function in an older population: The Rancho Bernardo Study
57. Effects of a two-week physiological DHEA substitution on cognitive performance and well-being in healthy elderly women and men
58. DHEA replacement in women with adrenal insufficiency
59. Trace concentrations of over-the-counter androstenedione and positive urine test results for a nandrolone metabolite
60. Oral androstenedione administration and serum testosterone concentrations in young men
61. The in vivo conversion of dehydroepiandrosterone and androstenedione to testosterone in the human
62. Effects of DHEA vs. androstenedione supplementation in men
63. Proerectile pharmacological effect of Tribulus terrestris extract on the rabbit corpus cavernosum
64. Tribulus terrestris does not alter body composition or exercise performance in resistance-trained males